Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial
Sarah Brown(University of Leeds), Jonathan Wadsley(Weston Park Cancer Centre), Kate Newbold(Royal Marsden NHS Foundation Trust), Rebecca Gregory(Barts Health NHS Trust), Andrew Hall(University of Leeds), Yong Du(Royal Marsden Hospital), Glenn Flux(Royal Marsden NHS Foundation Trust), David González de Castro(Complejo Hospitalario de Salamanca), Hannah Buckley(University of Leeds), Laura Moss(Velindre Cancer Centre), Kate Farnell(British Thyroid Foundation), Louise Flanagan(University of Leeds)
Cited by 39
Related Papers
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
|The Lancet Oncology|2013|728